Purpose: A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma. Patients and Methods: A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteria. Additional endpoints included safety and immune responses. Results: Between March 2016 and October 2019, 55 patients were randomized, of whom 48 were evaluable (24 in each group). The median progression-free survival time using RECIST criteria was 18.6 months in patients treated with chemoembolization + preconditioning cyclophosphamide + DC infusions compared with 10.4 months in those treated with chemoembolization + preconditioning cyclophosphamide alone (HR = 0.43; upper value of one-sided 80% confidence interval, 0.57; P = 0.016). The addition of DC infusions did not significantly increase the incidence or severity of adverse events. An enhanced antigen (α-fetoprotein)-specific immune response was observed in patients treated with DC vaccination. Conclusions: The addition of DC infusions to TACE and preconditioning cyclophosphamide has shown promising preliminary activity and merits further investigation in a larger randomized trial.
This review explores the evolving role of endoscopic ultrasound (EUS) in the diagnosis and management of liver diseases, with a particular focus on chronic liver disease, focal hepatic lesions, portal hypertension, and post-transplant anatomy. A comprehensive literature review of PubMed, MEDLINE, and Embase studies up to August 2025 was conducted to identify the latest evidence on EUS-guided procedures, comparing them with traditional techniques. In diagnostics, EUS-guided liver biopsy provides real-time visualisation and precise tissue sampling, achieving longer specimen lengths and better patient outcomes compared to traditional percutaneous and transjugular approaches. For portal hypertension assessment, EUS-guided portal pressure gradient measurement is a promising alternative to conventional methods, with validation studies demonstrating strong correlation with hepatic venous pressure gradient measurements. In therapeutic applications, EUS facilitates precise interventions including gastric variceal treatment through combined coil and glue injection, management of visceral arterial pseudoaneurysms, selective portal vein embolisation, and targeted tumour ablation. While some applications remain in developmental stages, studies support the safety and efficacy of EUS in improving diagnostic accuracy and expanding therapeutic options for liver diseases. Ongoing technological advances in needle design, imaging capabilities, and artificial intelligence integration are expected to further enhance the utility of EUS in hepatology.
The aetiology of PSC is unclear but may involve cholangiocyte injury resulting from an abnormal immune response to environmental exposure in genetically susceptible individuals.3 13 PSC most commonly affects men between the ages of 30 and 40 and usually occurs in the presence of …
1 August 2025 in Efficacy and Mechanism Evaluation
Background: A previous study by our group using dendritic cells pulsed ex vivo with the lysate of the HepG2 cell line showed clinical benefit with evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. This trial set out to investigate the activity of this vaccine in combination with chemoembolisation compared to chemoembolisation alone in patients with intermediate stage hepatocellular carcinoma. All patients also received a conditioning regimen comprising low-dose cyclophosphamide. Objectives: To determine whether the addition of a dendritic cell vaccine to chemoembolisation and preconditioning cyclophosphamide prolongs progression-free survival and warrants further investigation. Design: Multicentre, open-label, randomised Phase II trial. Setting: Three tertiary referral units in the United Kingdom: Queen Elizabeth Hospital, Birmingham; Aintree University Hospital/Clatterbridge Cancer Centre, Liverpool and Queen’s Medical Centre, Nottingham. Participants: Patients > 18 years with intermediate stage hepatocellular carcinoma, performance status 0–2 and Child–Pugh A/B7 liver function. Intervention: Preconditioning cyclophosphamide on Day 1 and Day 29 followed by chemoembolisation on Day 31 (± dendritic cell infusion), followed by further preconditioning cyclophosphamide on Days 60, 90 and 120 (± additional dendritic cell infusions on Days 62, 92 and 122). Main outcome measures: The primary endpoint was progression-free survival time using Response Evaluation Criteria in Solid Tumours v1.1 criteria. Secondary endpoints were progression-free survival time based on modified (m) Response Evaluable Criteria in Solid Tumours criteria, overall survival time, radiological response according to Response Evaluable Criteria in Solid Tumours 1.1 criteria, radiological response based on Modified Response Evaluable Criteria in Solid Tumours criteria, change in the serum alpha-fetoprotein tumour marker, toxicity using Common Terminology Criteria for Adverse Events v4.0 and immune response. Results: Between March 2016 and October 2019, 55 patients were randomised of whom 48 are evaluable (24 in each group). The progression-free survival time using Response Evaluable Criteria in Solid Tumours criteria was 18.6 months in patients treated with chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions (Group 2) compared to 10.4 months in those treated with chemoembolisation plus preconditioning cyclophosphamide alone (Group 1) (hazard ratio 0.43, upper value of one-sided 80% confidence interval 0.57; p = 0.016). Although not statistically powered, the progression-free survival time using Modified Response Evaluable Criteria in Solid Tumours criteria showed a similar magnitude of benefit (18.6 vs 10.8 months: hazard ratio 0.48, 95% confidence interval 0.22 to 1.02). The overall response rate (complete response and partial response) by Response Evaluable Criteria in Solid Tumours was 54% in Group 2 and 29% in Group 1 and the disease control rate (complete response, partial response and stable disease) was 92% in Group 2 and 67% in Group 1. Treatment with dendritic cell vaccination was associated with an enhanced antigen-specific immune response. Treatment was well tolerated with few additional adverse events from the additional dendritic cell infusions. Conclusions: Chemoembolisation plus preconditioning cyclophosphamide plus dendritic cell infusions merit further investigation in a randomised Phase III trial but the trial design will need to take into account the current evolving hepatocellular carcinoma treatment landscape. Limitations: The current dendritic cell manufacturing process limits large-scale use and further validation and automation of the process will be needed prior to testing in a randomised Phase III trial. Future Work: Further testing in a randomised Phase III trial is warranted. Trial registration: This trial is registered as ISRCTN11889464; EudraCT number: 2011-001690-62. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 09/160/24) and is published in full in Efficacy and Mechanism Evaluation; Vol. 12, No. 9. See the NIHR Funding and Awards website for further award information.